ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 152023" data-attributes="member: 13851"><p><strong>Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo controlled, Double-blind, Phase IIb Clinical Trial </strong></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">ABSTRACT </span></strong></p><p></p><p><strong>Purpose: </strong>Udenafil is an oral phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction. In a multicenter, placebo-controlled, randomized Phase IIa study, the reduction of pulmonary vascular resistance index was greater with a 50-mg baseline dose of udenafil than with the 100- mg dose, the cardiac index did not decrease at most points, and the safety was excellent, suggesting that 50-mg udenafil could be used in a Phase IIb trial.</p><p></p><p></p><p><strong>Methods:</strong> In this 16-week, double-blind, placebo controlled study, 63 patients with pulmonary arterial hypertension were randomized to receive 50-mg udenafil or a placebo BID. The primary efficacy end point was the 6-min walking distance. The secondary efficacy end points were the Borg dyspnea score and time to clinical worsening. Patients who completed the 16-week study could participate in a long-term extension study.</p><p></p><p></p><p><strong>Findings:</strong> In terms of the difference between the baseline and 16-week 6-min walking distance in both groups, the mean placebo-corrected treatment effect was 25 (58) m (P ¼ 0.0873). Among the patients with a history of endothelin receptor antagonist therapy, the treatment effect at week 16 between the udenafil and placebo groups was 34 (60) m (P ¼ 0.0460). However, there were no significant differences in the Borg dyspnea score and time to clinical worsening between groups. The safety profile and adverse effects of udenafil were similar to those of typical phosp</p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong>CONCLUSIONS </strong></p><p><strong><span style="color: rgb(184, 49, 47)">The favorable tolerability of udenafil and its positive effects on the 6-MWD and NT-proBNP </span>could potentially translate into improvements in health related quality of life for patients.</strong> <strong>The data obtained through the study<span style="color: rgb(184, 49, 47)"> show the efficacy of udenafil for the treatment of patients with PAH; moreover, udenafil seemed to be safe and well tolerated by patients.</span> Further extended study of udenafil in PAH is warranted. </strong></p></blockquote><p></p>
[QUOTE="madman, post: 152023, member: 13851"] [B]Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo controlled, Double-blind, Phase IIb Clinical Trial [/B] [B][COLOR=rgb(184, 49, 47)]ABSTRACT [/COLOR][/B] [B]Purpose: [/B]Udenafil is an oral phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction. In a multicenter, placebo-controlled, randomized Phase IIa study, the reduction of pulmonary vascular resistance index was greater with a 50-mg baseline dose of udenafil than with the 100- mg dose, the cardiac index did not decrease at most points, and the safety was excellent, suggesting that 50-mg udenafil could be used in a Phase IIb trial. [B]Methods:[/B] In this 16-week, double-blind, placebo controlled study, 63 patients with pulmonary arterial hypertension were randomized to receive 50-mg udenafil or a placebo BID. The primary efficacy end point was the 6-min walking distance. The secondary efficacy end points were the Borg dyspnea score and time to clinical worsening. Patients who completed the 16-week study could participate in a long-term extension study. [B]Findings:[/B] In terms of the difference between the baseline and 16-week 6-min walking distance in both groups, the mean placebo-corrected treatment effect was 25 (58) m (P ¼ 0.0873). Among the patients with a history of endothelin receptor antagonist therapy, the treatment effect at week 16 between the udenafil and placebo groups was 34 (60) m (P ¼ 0.0460). However, there were no significant differences in the Borg dyspnea score and time to clinical worsening between groups. The safety profile and adverse effects of udenafil were similar to those of typical phosp [B]CONCLUSIONS [COLOR=rgb(184, 49, 47)]The favorable tolerability of udenafil and its positive effects on the 6-MWD and NT-proBNP [/COLOR]could potentially translate into improvements in health related quality of life for patients.[/B] [B]The data obtained through the study[COLOR=rgb(184, 49, 47)] show the efficacy of udenafil for the treatment of patients with PAH; moreover, udenafil seemed to be safe and well tolerated by patients.[/COLOR] Further extended study of udenafil in PAH is warranted. [/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top